Trastuzumab-based regimens beyond progression: A crucial treatment option for HER2+ advanced/metastatic breast cancer

Upon its establishment for the treatment of metastatic breast cancer (mBC), continuing trastuzumab beyond disease progression was an important paradigm shift that became the recommendation by major guidelines. However, data supporting continuation of human epidermal growth factor receptor 2 (HER2) b...

Descripción completa

Detalles Bibliográficos
Autores principales: Sanglier, Thibaut, Ross, Ryan, Shi, Tianlai, Mouta, João, Swain, Sandra, Cardoso, Fatima
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663523/
https://www.ncbi.nlm.nih.gov/pubmed/36375387
http://dx.doi.org/10.1016/j.breast.2022.10.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663523/
https://www.ncbi.nlm.nih.gov/pubmed/36375387
http://dx.doi.org/10.1016/j.breast.2022.10.008

Ejemplares similares